Testing different drug combos for HER2-positive breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests different combinations of the drug Inetetamab as a first treatment for breast cancer that has spread and is HER2-positive. It aims to find which combo works best and is safe for newly diagnosed metastatic patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old.
- Your breast cancer is HER2-positive (a type that grows fast).
- It has spread to other parts of your body (or came back in a spot that can’t be removed with surgery).
- You have not had any anti-HER2 treatment for this stage of cancer, or you finished treatment more than 12 months ago.
- You are generally well enough to get out and about (ECOG score 0-2) and have an expected survival of at least 6 months.
- Your heart function is normal (LVEF 50% or more on an echo).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how well and how safely different combinations of cancer drugs work for people with metastatic or inoperable locally advanced breast cancer. It may help by finding a better treatment option and collecting information to guide future care.
This trial tests a new drug called RC48 combined with chemotherapy for people with HER2-positive advanced breast cancer that has worsened after treatment with a specific type of antibody-drug conjugate (a drug that targets cancer cells). The goal is to see if this new combination can help when other treatments have stopped working.
This trial compares two drug combinations for HER2-positive breast cancer that has spread. It tests a newer drug (Disitamab Vedotin + Pyrotinib) against a standard treatment (THP) as a first treatment option.
This trial tests a combination of targeted therapies (trastuzumab and pertuzumab) with chemotherapy (docetaxel) and an experimental drug (QL1706) given before surgery to shrink early or locally advanced HER2-positive breast cancer. It aims to see if this approach improves outcomes before definitive surgery.
This study tests a drug called inetetamab as a first treatment for HER2-positive breast cancer that has spread or cannot be removed by surgery. It aims to see how well it works in real-world settings.
This trial tests whether inetetamab combined with pyrotinib and vinorelbine works better and is safe for adults with HER2-positive advanced breast cancer. You may be considered if standard options have not removed the cancer with surgery and your body can handle chemotherapy and HER2-targeting medicines.
Hear when a new Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.